Back to Authors

Stahl, Maximilian

https://orcid.org/0000-0002-1299-5901

A5013969487 | I2802730090

Mayo Clinic

Yale Cancer Center

Citations 23

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Leukemia & Lymphoma | July 2, 2018 | Volume: 60 | Issue: 1 | Pages: 246-249

10.1080/10428194.2018.1468893 | PMID 29963936

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Blood Advances | April 23, 2018 | Volume: 2 | Issue: 8 | Pages: 923-932

10.1182/bloodadvances.2018016121 | PMID 29685952

Key Points In the largest study of HMAs in RR-AML to date, 16% of patients achieved CR/CRi and experienced a median OS of 21 months. Low proliferative disease (peripheral blood blasts <5%) was associated with improved response and OS.
Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey

Leukemia & Lymphoma | April 18, 2018 | Volume: 59 | Issue: 11 | Pages: 2723-2726

10.1080/10428194.2018.1452219 | PMID 29667455